BioNTech (NASDAQ:BNTX) Upgraded by Jefferies Financial Group to Buy

Jefferies Financial Group upgraded shares of BioNTech (NASDAQ:BNTX) from a hold rating to a buy rating in a research note issued to investors on Tuesday morning, MarketBeat reports. They currently have $150.00 price objective on the stock, up from their prior price objective of $96.00.

Other equities analysts have also recently issued research reports about the stock. HSBC raised shares of BioNTech from a hold rating to a buy rating in a research report on Friday, August 2nd. Hsbc Global Res upgraded BioNTech from a hold rating to a strong-buy rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. raised BioNTech from an underweight rating to a neutral rating and upped their price target for the company from $91.00 to $125.00 in a research report on Monday. Bank of America lifted their price objective on shares of BioNTech from $125.00 to $150.00 and gave the stock a buy rating in a report on Monday. Finally, HC Wainwright reissued a buy rating and set a $113.00 target price on shares of BioNTech in a report on Monday. Six analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $118.00.

BioNTech Price Performance

Shares of NASDAQ BNTX opened at $124.71 on Tuesday. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The business has a 50 day moving average price of $88.13 and a two-hundred day moving average price of $89.90. The firm has a market cap of $29.65 billion, a PE ratio of 249.42 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The company had revenue of $128.70 million during the quarter, compared to the consensus estimate of $134.98 million. During the same quarter last year, the firm posted ($0.86) EPS. The firm’s quarterly revenue was down 23.3% on a year-over-year basis. Sell-side analysts expect that BioNTech will post -2.8 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC boosted its position in BioNTech by 121.0% during the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after acquiring an additional 150 shares during the period. Frazier Financial Advisors LLC acquired a new stake in BioNTech in the fourth quarter worth about $30,000. Covestor Ltd grew its position in BioNTech by 47.2% in the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after buying an additional 133 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in BioNTech by 106.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after buying an additional 252 shares during the period. Finally, Crewe Advisors LLC bought a new stake in shares of BioNTech during the 1st quarter worth about $75,000. 15.52% of the stock is owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.